Enamel matrix derivative exhibits Anti-inflammatory properties in monocytes

Journal of Periodontology

Volumn 79, Issue 3, 2008, Pages 535-540

  Sato, Sunao ^a   Kitagawa, Masae ^b   Sakamoto, Kiyako ^a   Iizuka, Shinji ^a   Kudo, Yasusei ^a   Ogawa, Ikuko ^b   Miyauchi, Mutsumi ^a   Chu, Emily Y ^c   Foster, Brian L ^c   Somerman, Martha J ^c   Takata, Takashi ^a,d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Emdogain; In monocytes; Inflammation; PGEand PGE2; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; ENAMEL MATRIX PROTEINS; ENAMEL PROTEIN; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ESCHERICHIA COLI; METABOLISM; MONOCYTE; RAT;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DENTAL ENAMEL PROTEINS; DINOPROSTONE; ESCHERICHIA COLI; LIPOPOLYSACCHARIDES; MONOCYTES; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41449115496     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.070311     Document Type: Article

References (35)

1. Hammarström L, Heijl L, Gestrelius S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997;24:669-677.
2. Giannobile WV, Somerman MJ. Growth and amelogenin-like factors in periodontal wound healing. A systemic review. Ann Periodontol 2003;8:193-204.
3. Venezia E, Goldstein M, Boyan BD, Schwartz Z. The use of enamel matrix derivative in the treatment of periodontal defects: A literature review and metaanalysis. Crit Rev Oral Biol Med 2004;15:382-402.
4. Esposito M, Grusovin MG, Coulthard P, Worthington HV. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. Cochrane Database Syst Rev 2005;(4):CD003875.
5. van der Pauw MT, van den Bos T, Everts V, Beertsen W. Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblasts and enhances alkaline phosphatase activity and transforming growth factor betal release of periodontal ligament and gingival fibroblasts. J Periodontol 2000;71:31-43.
6. Gestrelius S, Andersson C, Lidstrom D, Hammarstrom L, Somerman M. In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol 1997;24:685-692.
7. Hakki SS, Berry JE, Somerman MJ. The effect of enamel matrix protein derivative on follicle cells in vitro. J Periodontol 2001;72:679-687.
8. Parkar MH, Tonetti M. Gene expression profiles of periodontal ligament cells treated with enamel matrix proteins in vitro: Analysis using cDNA arrays. J Periodontol 2004;75:1539-1546.
9. Barrett EJ, Kenny DJ, Tenenbaum HC, Sigal MJ, Johnston DH. Replantation of permanent incisors in children using Emdogain. Dent Traumatol 2005;21: 269-275.
10. Wennström JL, Lindhe J. Some effects of enamel matrix proteins on wound healing in the dento-gingival region. J Clin Periodontol 2002;29:9-14.
11. Melcher AH. On the repair potential of periodontal tissues. J Periodontol 1976;47:256-260.
12. Meyer JR. The regenerative potential of the periodontal ligament. J Prosthet Dent 1986;55:260-265.
13. Egelberg J. Regeneration and repair of periodontal tissues. J Periodontal Res 1987;22:233-242.
14. Pitaru S, McCulloch CA, Narayanan SA. Cellular origins and differentiation control mechanisms during periodontal development and wound healing. J Periodontal Res 1994;29:81-94.
15. Cochran DL, Wozney JM. Biological mediators for periodontal regeneration. Periodontol 2000 1999;19: 40-58.
16. Hagenaars S, Louwerse PHG, Timmerman MF, van der Velden, van der Weijden GA. Soft-tissue wound healing following periodontal surgery and Emdogain application. J Clin Periodontol 2004;31:850-856.
17. St. George G, Darbar Thomas G. Inflammatory external root resorption following surgical treatment for intra-bony defects: A report of two cases involving Emdogain and a review of the literature. J Clin Periodontol 2006;33:449-454.
18. Giannopoulou C, Andersen E, Brochut P, Plagnat D, Mombelli A. Enamel matrix derivative and systemic antibiotics as adjuncts to non-surgical periodontal treatment: Biologic response. J Periodontol 2006;77: 707-713.
19. Graves DT, Oskoui M, Volejnikova S, et al. Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast formation in response to P. gingivalis infection. J Dent Res 2001;80:1875-1879.
20. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275:4858-4864.
21. Rifas L. Bone and cytokines: Beyond IL-1, IL-6 and TNF-alpha. Calcif Tissue Int 1999;64:1-7.
22. Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 1998;161:3071-3076.
23. Sakai T, Kambe F, Mitsuyama H, et al. Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: Abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors. J Bone Miner Res 2001;16:1272-1280.
24. Hong CY, Lin SK, Kok SH, et al. The role of lipopoly-saccharide in infectious bone resorption of periapical lesion. J Oral Pathol Med 2004;33:162-169.
25. Okaji M, Sakai H, Sakai E, et al. The regulation of bone resorption in tooth formation and eruption processes in mouse alveolar crest devoid of cathepsin k. J Pharmacol Sci 2003;91:285-294.
26. Takashiba S, Naruishi K, Murayama Y. Perspective of cytokine regulation for periodontal treatment: Fibroblast biology. J Periodontol 2003;74:103-110.
27. Offenbacher S. Periodontal diseases: Pathogenesis. Ann Periodontol 1996;1:821-878.
28. Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. Flurbiprofen: A potent inhibitor of alveolar bone resorption in beagles. Science 1985;227:640-642.
29. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775-779.
30. Hilkens C, Snijders A, Vermeulen H, van der Meide P, Wierenga E, Kapsenberg M. Accessory cell-derived interleukin-12 and prostaglandin E2 determine the level of interferon-gamma produced by activated human CD4+ T cells. Ann N Y Acad Sci 1996;795: 349-350.
31. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr., Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277:44147-44154.
32. Shinomiya S, Naraba H, Ueno A, et al. Regulation of TNF-alpha and interleukin-10 production by prostaglandins 1(2) and E(2): Studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol 2001 ;61:1153-1160.
33. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004;200:400-406.
34. Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci USA 2002;99:4580-4585.
35. Ramirez-Yañez GO, SeymourGJ, Walsh LJ, ForwoodMR, Symons AL. Prostaglandin E2 enhances alveolar bone formation in the rat mandible. Bone 2004;35:1361 -1368.